Junctional scotoma of Traquair

“Junctional scotoma of Traquair” is a specific visual field loss pattern that happens when a lesion (often a tumor, cyst, aneurysm, or inflammation) sits right where the optic nerve meets the optic chiasm (the “junction”). The field loss is in one eye only and looks like a half-field missing on the temporal (outer) or, less commonly, the nasal (inner) side, neatly respecting the vertical midline. In other words, one eye loses the right or left half of its sight, straight up and down. This precise shape is what Traquair described. EyeWiki

By contrast, the classic “junctional scotoma” (without “of Traquair”) means two-eye involvement but in a very specific way: one eye has a central-type loss (like a blurred or dark patch where you fixate), and the other eye loses the upper outer (superotemporal) part of its field. This pattern also points to a lesion exactly at the optic nerve–chiasm junction. EyeWikiNCBI

Why here? That junction is where nerve fibers cross from each eye. So a small mass there can nick one set of fibers more than another, creating highly localizing field patterns that help doctors pinpoint the lesion’s location. EyeWiki

---

The essential anatomy

• Optic nerve: the cable carrying signals from one eye to the brain.

• Optic chiasm: a small X-shaped structure where some fibers cross to the other side.

• Nasal retina fibers (inner half of the retina) cross; temporal retina fibers (outer half) don’t. Because of this wiring, damage at the chiasm/junction creates distinctive temporal-side field losses (the outer halves) or the Traquair-type monocular vertical hemifield loss depending on exactly which fiber bundle is squeezed. EyeWikiNCBI

A helpful modern note: the old idea called “Wilbrand’s knee” (a little forward loop of crossing fibers used to explain some patterns) is now considered an artifact that shows up in animals long after an eye is removed; it does not exist in the normal chiasm. We still see the clinical pattern, but we no longer rely on that “knee” to explain it. PubMedPMC

---

Types

1. Junctional scotoma (classic pattern):

   • One eye: central-type loss (blurred spot, scotoma, reduced detail).

   • Other eye: superotemporal (upper outer) field loss that respects the vertical midline.

   • Meaning: lesion at the optic nerve–chiasm junction involving the ipsilateral optic nerve and the crossing inferior-nasal fibers of the opposite eye. NCBIEyeWiki

2. Junctional scotoma of Traquair (monocular hemianopia):

   • One eye only loses a right or left half of its field (temporal half is typical; nasal half is rare), cleanly split by the vertical meridian.

   • Meaning: lesion at the same junction, but picking off a different fiber bundle so only one eye’s half-field is affected. EyeWiki

3. Atypical variants (less common):

   • You may see a lower temporal or other non-standard variant depending on the exact compression angle (ventral vs dorsal, etc.) or a non-compressive disease. These variants exist but are less frequent. PubMed

---

Causes

Key idea: Most cases are compressive masses in the sellar/parasellar region (the area around the pituitary and chiasm). The single most common cause is a pituitary adenoma (a pituitary tumor). Other culprits include meningiomas, craniopharyngiomas, cysts, and aneurysms. Inflammatory, demyelinating, and infectious disorders can also do it, especially when imaging doesn’t show a big mass. NCBIEyeWiki

1. Pituitary macroadenoma (most common) — grows upward from the sella and presses the chiasm/junction. NCBI

2. Pituitary apoplexy — sudden bleeding or infarct inside a pituitary tumor causing acute chiasmal compression and abrupt visual loss. WikiDoc

3. Craniopharyngioma — a benign tumor from pituitary-area remnants; can push the chiasm from behind/above. NCBI

4. Rathke’s cleft cyst — a benign cyst in the same area; can compress the chiasm and mimic tumors. NCBI

5. Tuberculum sellae meningioma — a meningioma from the skull base that rises beneath the chiasm. Ozhurnal

6. Planum sphenoidale/medial sphenoid wing meningioma — similar skull-base tumors, sometimes extending to the optic nerve sheath and junction. Thai Journal Online

7. Optic nerve sheath meningioma — wraps the nerve and, near the chiasm, can produce junctional patterns. PMC

8. Optic pathway glioma/pilocytic astrocytoma — more common in children; can involve the chiasm. NCBI

9. Internal carotid or anterior communicating artery aneurysm — pulsatile vascular enlargement that indents the junction. NCBI

10. Suprasellar arachnoid cyst — a fluid-filled sac that can compress the chiasm; sometimes reversible after fenestration. ScienceDirectAmerican Journal of Neuroradiology

11. Rathke’s cleft cyst with acute expansion — even without bleeding, sudden size change can worsen vision quickly. PMC

12. Cysticercosis (suprasellar) — parasitic cysts may inflame or press on the chiasm. Lippincott Journals

13. Inflammatory granulomatous disease (e.g., sarcoidosis) — can enhance the optic nerve/chiasm and mimic a mass. EyeWiki

14. Demyelinating disease (e.g., multiple sclerosis, neuromyelitis optica spectrum disorders) — inflammation at or near the junction can create “anterior chiasmal syndrome.” ClinMed Journals

15. Infiltrative disease (e.g., lymphoma, leukemia) — infiltrates the anterior visual pathway and produces junctional patterns. EyeWiki

16. Metastatic tumors (e.g., breast, lung) — may seed the optic nerve sheath or parasellar region. Clinical Gate

17. Pituitary/hypothalamic congenital variants with tight space — small masses compress sooner depending on chiasm “positioning” (prefixed/postfixed). Retina TodayCRSToday

18. Trauma/surgical injury to the chiasm region — direct damage or scarring at the junction. (General mechanistic inclusion; see chiasm reviews.) EyeWiki

19. Ischemia (reduced blood flow) of the anterior visual pathway — rare at the junction but reported in chiasmal syndromes. (General chiasm syndrome context.) EyeWiki

20. Large sellar cystic lesions of other types (e.g., complex cysts) — uncommon but documented causes of chiasmal compression and field loss. ScienceDirect

---

Symptoms

1. Blurred or dim central vision in one eye — words smudge, faces seem off, or you need more light.

2. Half-side missing in one eye — a clean vertical cut on the outer (temporal) side is typical in the Traquair pattern; the inner (nasal) side is rarer. EyeWiki

3. A gray or dark patch (scotoma) that doesn’t move with blinking and is always in the same place.

4. Colors look washed-out, especially red (red desaturation) in the more affected eye.

5. Poor contrast — fine print, low-contrast signs, or misty days are harder.

6. Bumping into things on one side, especially doorframes or people, when only one eye is open.

7. Headache or pressure — common when the cause is a growing mass like a pituitary adenoma. EyeWiki

8. Endocrine symptoms if the cause is a pituitary tumor (for example, irregular periods or lactation in women, low libido or erectile dysfunction in men, thyroid or growth-hormone changes). NCBI

9. Double vision if nearby nerves in the cavernous sinus are irritated (less common but possible with extension). NCBI

10. Eye ache or retro-orbital pain if there’s acute expansion (e.g., apoplexy) or inflammation. WikiDoc

11. Photophobia (light sensitivity) in some chiasmal compressions. EyeWiki

12. Subtle awareness of missing letters on a page — like holes in lines of text with one eye closed.

13. Difficulty reading because the central spot and the temporal half-field help us track words.

14. Unequal pupil reaction picked up by clinicians (a relative afferent pupillary defect) in the more damaged pathway. EyeWiki

15. No symptom at all in the “other” eye despite a superotemporal loss — the brain can hide it, which is why formal field testing is crucial. EyeWiki

---

Diagnostic tests

Big picture: diagnosis relies on careful eye exam, formal visual fields, and MRI targeted to the pituitary/chiasm. OCT (optical coherence tomography) adds objective structure, and sometimes VEP (visual evoked potentials) helps confirm pathway dysfunction. Hormone labs matter when a pituitary problem is suspected.

A) Physical exam

1. Visual acuity with pinhole
   Checks the best-corrected sharpness of sight and screens out blur from glasses/focus problems. Central drop in one eye supports the “junctional” picture.

2. Pupil exam with swinging flashlight (RAPD test)
   Looks for unequal light reaction pointing to optic nerve pathway damage on one side — very common with junctional lesions. EyeWiki

3. Color vision test (Ishihara or HRR)
   Simple dot-plate tests: loss of red/green discrimination supports optic nerve/chiasmal dysfunction (colors fade early).

4. Dilated optic nerve head exam
   The doctor looks for optic pallor and a pattern called band (bow-tie) atrophy when nasal or temporal fibers are lost — a classic clue in chiasmal/anterior pathway disease. NCBIWebEyeAmerican Academy of Ophthalmology

B) Manual visual function tests

5. Confrontation visual fields
   A quick, bedside check where you cover one eye and count fingers in different quadrants. It can hint at a vertical hemifield loss or the superotemporal notch in the fellow eye — but it’s only a screen.

6. Amsler grid
   The checkered grid you stare at to find wavy or missing central areas (scotomas). Helps flag the central part of a junctional defect.

7. Red desaturation test
   Comparing how bright a red object looks between eyes; a faded red in one eye often signals optic nerve involvement.

8. Brightness sense comparison
   Patients judge which eye sees a light as brighter; dimmer suggests afferent pathway damage.

9. Kinetic manual perimetry (Goldmann/Tangent screen)
   A trained technician maps your visual field by moving lights of different sizes/brightness. Great for localizing the Traquair monocular hemifield pattern and the superotemporal notch of the fellow eye in classic junctional scotoma. EyeWiki

C) Lab and pathology tests

10. Pituitary hormone panel
    Blood tests for prolactin, IGF-1, morning cortisol/ACTH, TSH/free T4, LH/FSH, and sex hormones. Abnormalities point toward a functional adenoma and guide therapy. NCBI

11. Inflammation markers (ESR, CRP)
    Elevated levels are clues to inflammatory or vasculitic causes (e.g., sarcoid), especially when imaging does not show a big mass. EyeWiki

12. Autoimmune/demyelinating antibodies
    AQP4-IgG and MOG-IgG can support NMOSD/MOGAD if imaging shows enhancement instead of a big compressive lesion. EyeWiki

13. Infectious serology
    Syphilis tests (RPR/VDRL with treponemal confirmation), TB IGRA, and sometimes ACE (for sarcoidosis) help when inflammatory/infectious causes are suspected. EyeWiki

D) Electrodiagnostic tests

14. Pattern VEP (visual evoked potential)
    Measures electrical responses in the brain to checkerboard patterns. Delayed or reduced signals support optic nerve/chiasmal dysfunction; hemifield VEPs can even hint at chiasmal involvement. NCBIPubMedPMC

15. Hemifield VEP (half-field stimulation)
    Stimulates right vs left halves of the visual scene separately; abnormal asymmetry can localize dysfunction to the chiasm or behind it. iscev.org

16. Pattern ERG (electroretinogram)
    Checks retinal ganglion cell function. A relatively preserved ERG with abnormal VEP suggests a post-retinal problem (optic nerve/chiasm), helping rule out primary macular disease. NCBI

E) Imaging tests

17. MRI of brain/orbits with contrast (pituitary protocol)
    The key test. It shows the sellar/parasellar region, the optic nerves, and the chiasm. It’s preferred over CT for pituitary/chiasm evaluation and guides surgery when needed. NCBI

18. MR angiography (MRA) or CT angiography (CTA)
    Looks for aneurysms (e.g., anterior communicating or internal carotid) that can compress the junction. NCBI

19. OCT (optical coherence tomography) of macula and RNFL
    A quick, painless scan of retinal nerve layers. In chiasmal compression, the macular ganglion cell/inner plexiform layer (GCIPL) and RNFL show characteristic thinning patterns (often vertical nasal thinning) that can precede field loss and predict recovery after decompression. PMCPLOSNatureLippincott Journals

20. Automated static perimetry (Humphrey 24-2/30-2; 10-2 as needed)
    The gold-standard map of your visual field. It captures the Traquair monocular hemifield neatly and the superotemporal defect in the fellow eye (classic junctional scotoma). It’s also essential for follow-up. EyeWiki

Non-pharmacological treatments

1. Urgent localization and imaging
   Purpose: Pinpoint the lesion quickly. Mechanism: MRI/MRA guides whether surgery, radiation, or medical therapy is needed; time is vision. American Journal of Neuroradiology

2. Endocrinology co-management
   Purpose: Address hormone excess/deficiency from pituitary disease. Mechanism: Stabilizing cortisol/thyroid/other axes supports vision recovery after decompression. EyeWiki

3. Observation with close follow-up (select tiny, asymptomatic sellar lesions)
   Purpose: Avoid overtreatment. Mechanism: Serial fields/OCT/MRI ensure stability; intervene if progression appears. EyeWiki

4. Vision rehabilitation consult
   Purpose: Maximize day-to-day function. Mechanism: Personalized strategies, task lighting, contrast tweaks, route planning.

5. Orientation & mobility training
   Purpose: Safer walking and navigation. Mechanism: Teaches scanning/sweeping to compensate for the temporal gap.

6. Visual scanning therapy
   Purpose: Faster detection of obstacles on the blind side. Mechanism: Repetitive eye-movement patterns enlarge effective “functional field.”

7. Low-vision aids
   Purpose: Reading and detailed work. Mechanism: Magnifiers, electronic readers, high-contrast modes, screen readers.

8. Workplace/school accommodations
   Purpose: Maintain productivity. Mechanism: Seat placement, enlarged fonts, double-monitors, layout changes.

9. Driving counseling
   Purpose: Keep you and others safe. Mechanism: Assess legal fitness; suggest retraining or alternatives.

10. Lighting optimization
    Purpose: Reduce glare, boost contrast. Mechanism: Task lights, matte surfaces, anti-glare coatings.

11. Fatigue management
    Purpose: Reduce visual strain. Mechanism: 20-20-20 breaks, scheduled rests, ergonomic setup.

12. Head-posture and scanning habits
    Purpose: Bring the blind side into view. Mechanism: Small, deliberate head turns while walking/reading.

13. Fall-prevention home changes
    Purpose: Safety. Mechanism: Clear hallways, label edges, high-contrast stair strips.

14. Psychological support
    Purpose: Cope with sudden vision change. Mechanism: Counseling, peer groups.

15. Treat sleep apnea & cardiometabolic risks
    Purpose: Support optic-nerve health in vascular or compressive contexts. Mechanism: Improves perfusion/oxygenation.

16. Smoking cessation & alcohol moderation
    Purpose: Reduce optic-neuropathy risk and improve healing. Mechanism: Lowers toxic/ischemic stress on axons.

17. Radiation therapy (when indicated)
    Purpose: Control tumors not ideal for immediate surgery (some meningiomas, residual/recurrent adenomas). Mechanism: Stereotactic radiosurgery or fractionated RT arrests growth, relieving pressure over time. EyeWiki

18. Endovascular treatment planning for aneurysm
    Purpose: Decide on coil/stent vs. surgery. Mechanism: Removes the pulsatile compressive source. EyeWiki

19. Prompt sinus/ENT evaluation (suspected invasive sinus disease)
    Purpose: Source control. Mechanism: Endoscopic drainage/debridement reduces junctional pressure. EyeWiki

20. Assistive tech & accessibility settings
    Purpose: Make phones/computers easier. Mechanism: High-contrast themes, zoom, voice interfaces.

---

Drug treatments

1. IV Methylprednisolone (glucocorticoid)
   Dose/Time: 1 g/day IV for 3–5 days, then oral taper if inflammatory chiasmitis/neuritis.
   Purpose/Mechanism: Rapid anti-inflammatory effect to limit demyelinating or autoimmune damage.
   Key side effects: High glucose, mood/sleep change, infection risk, gastritis.

2. Prednisone taper (glucocorticoid)
   Dose/Time: Often 1 mg/kg/day short course after IV pulse, taper over weeks.
   Purpose: Consolidate steroid response.
   Side effects: As above plus weight gain, hypertension.

3. Cabergoline (dopamine agonist) for prolactinoma
   Dose/Time: 0.25–0.5 mg twice weekly, titrate to normalize prolactin.
   Purpose/Mechanism: Shrinks prolactin-secreting pituitary tumors, relieving chiasmal pressure.
   Side effects: Nausea, hypotension, headache; rare valvular disease with high cumulative doses. EyeWiki

4. Bromocriptine (dopamine agonist) — alternative to cabergoline
   Dose/Time: 1.25–2.5 mg 1–2×/day, titrate.
   Purpose/Mechanism/Side effects: As above. EyeWiki

5. Octreotide LAR (somatostatin analog) for GH- or TSH-secreting adenomas
   Dose/Time: 20 mg IM every 4 weeks to start.
   Purpose/Mechanism: Hormone control and tumor stabilization/shrinkage.
   Side effects: GI upset, gallstones, glucose changes. EyeWiki

6. Temozolomide (alkylating agent) for aggressive pituitary tumors (rare)
   Dose/Time: 150–200 mg/m² PO daily days 1–5 every 28 days.
   Purpose/Mechanism: Anti-tumor cytotoxic therapy when surgery/RT fail.
   Side effects: Myelosuppression, nausea, fatigue. EyeWiki

7. Amphotericin B (liposomal) for invasive fungal sinusitis
   Dose/Time: ~5 mg/kg/day IV, with ENT surgery.
   Purpose/Mechanism: Fungicidal membrane disruption; life-saving source control.
   Side effects: Kidney injury, electrolyte loss, infusion reactions. EyeWiki

8. Antitubercular therapy (HRZE-based regimen) for tuberculoma
   Dose/Time: Weight-based daily per national guideline (often 2 months intensive + continuation).
   Purpose/Mechanism: Eradicate Mycobacterium tuberculosis; shrink granuloma.
   Side effects: Hepatotoxicity, optic neuropathy risk with ethambutol (requires visual monitoring). EyeWiki

9. Rituximab (anti-CD20) for AQP4+ NMOSD or refractory inflammatory optic neuritis
   Dose/Time: 1 g IV day 1 & 15, then ~q6 months (or 375 mg/m² weekly ×4).
   Purpose/Mechanism: B-cell depletion to prevent attacks that could involve chiasm/optic nerve.
   Side effects: Infusion reactions, infections (screen for HBV).

10. Eculizumab (C5 inhibitor) for AQP4+ NMOSD
    Dose/Time: 900 mg weekly ×4, then 1200 mg week 5, then 1200 mg q2w.
    Purpose/Mechanism: Blocks complement-mediated astrocyte injury.
    Side effects: Meningococcal infection risk (vaccination required). EyeWiki

Important: the list above is cause-directed; your team will tailor the exact drug, dose, and timing to your diagnosis.

---

Dietary / molecular & supportive supplements

(Evidence for reversing a junctional scotoma is limited; think of these as general optic-nerve/brain-health supports. Always clear supplements with your clinicians—some interact with tumor or immune therapies.)

1. Vitamin B12 (methylcobalamin 1000 µg/day) — supports myelin & axons; deficiency causes optic neuropathy.

2. Folate (0.4–1 mg/day) — one-carbon metabolism for neural repair.

3. Thiamine (B1 50–100 mg/day) — neuronal energy handling.

4. Riboflavin (B2 25–100 mg/day) — mitochondrial function.

5. Vitamin D3 (1000–2000 IU/day, individualized) — immune modulation & bone/nerve support.

6. Omega-3s (EPA+DHA ~1 g/day) — anti-inflammatory membrane effects.

7. Vitamin C (500 mg/day) — antioxidant support.

8. Vitamin E (up to 200 IU/day) — lipid antioxidant (avoid high doses without guidance).

9. Lutein/Zeaxanthin (10 mg/2 mg/day) — retinal antioxidant pigments.

10. Alpha-lipoic acid (300–600 mg/day) — antioxidant, may aid neuropathic symptoms.

11. Coenzyme Q10 (100–200 mg/day) — mitochondrial support.

12. N-acetylcysteine (600–1200 mg/day) — glutathione precursor.

13. Magnesium (200–400 mg/day) — neuronal excitability & headaches.

14. Zinc (≤25 mg/day) — immune support (avoid excess; can lower copper).

15. Taurine (500–1000 mg/day) — retinal/neuronal osmotic balance (limited human data).

---

Immune / regenerative / “stem-cell”–type drugs

1. Rituximab — B-cell depletion for NMOSD-related optic/chiasmal disease; dosing as above; reduces relapses. Risks: infection, hypogammaglobulinemia. EyeWiki

2. Eculizumab — terminal complement blockade; powerful relapse prevention in AQP4+ NMOSD; vaccine prerequisites. EyeWiki

3. Satralizumab — anti-IL-6 receptor biologic for NMOSD (120 mg SC at weeks 0, 2, 4, then every 4 weeks). Side effects: infection risk, lab changes. EyeWiki

4. Inebilizumab — anti-CD19 B-cell depletion (300 mg IV day 1 & 15, then every 6 months) for NMOSD. Similar safety considerations. EyeWiki

5. Azathioprine or Mycophenolate mofetil — older steroid-sparing immunosuppressants used off-label to reduce inflammatory relapses; require lab monitoring.

6. Stem-cell approaches (AHSCT or “intravitreal stem cells”) — experimental; not standard for junctional scotoma or compressive chiasmal disease; some commercial offerings have caused serious harm (retinal detachment, blindness). Consider only within regulated clinical trials after multidisciplinary review.

---

Surgeries/procedures

1. Endoscopic endonasal transsphenoidal surgery (EETS)
   What: Through the nose, the surgeon removes a pituitary adenoma or similar sellar mass.
   Why: Fastest way to relieve pressure on the optic nerve–chiasm junction; often leads to measurable field improvement if done early. EyeWiki

2. Transcranial resection of tuberculum sellae/planum meningioma with optic canal decompression
   What: Craniotomy to remove a skull-base meningioma and unroof the optic canal.
   Why: Directly removes the compressive source and frees the junctional fibers. EyeWiki

3. Endovascular aneurysm treatment (coiling / flow diversion / stent-assisted coiling)
   What: Catheter-based repair of an ICA/ACoA aneurysm.
   Why: Eliminates pulsatile compression on the chiasm/nerve junction and prevents rupture. EyeWiki

4. Endoscopic sinus surgery with debridement (e.g., mucocele or invasive fungal sinusitis)
   What: ENT removes infected tissue and drains pressure.
   Why: Rapid source control and decompression; combined with antifungals when needed. EyeWiki

5. Craniopharyngioma resection (endoscopic or open, tailored to anatomy)
   What: Removal of a cystic/solid tumor near the chiasm.
   Why: Debulks or cures the lesion compressing junctional fibers. EyeWiki

Timing matters: earlier decompression generally means better odds of visual recovery. American Journal of Neuroradiology

---

Prevention

You can’t always prevent a junctional scotoma, but you can lower risks and catch problems early:

1. Know red-flag symptoms (side-vision loss, color washout, new severe headache). Seek care early. EyeWiki

2. Regular eye exams if you have pituitary disease or endocrine symptoms. EyeWiki

3. Manage blood pressure, diabetes, lipids (helps vascular/aneurysm risk).

4. Don’t ignore sinus infections that worsen quickly, especially with diabetes/immunosuppression. EyeWiki

5. Vaccinate and control infections that can spread to the skull base when relevant.

6. Treat autoimmune disease per specialist plans to reduce relapses involving optic pathways. EyeWiki

7. Avoid neurotoxic exposures (tobacco, excess alcohol; monitor drugs like ethambutol if prescribed).

8. Use protective headgear to reduce traumatic causes. The Journal of Medical Optometry (JoMO)

9. Follow imaging follow-up schedules for known sellar/parasellar lesions. EyeWiki

10. Maintain good sleep and nutrition, supporting nerve health.

---

When to see a doctor

• Immediately / emergency: sudden new temporal half-field loss in one eye; severe headache with vomiting or sudden vision drop (possible pituitary apoplexy); painful eye movement with vision decline; abrupt hormonal crisis symptoms. EyeWiki

• Urgent (within days): progressive side-vision loss, new color desaturation, new endocrine symptoms (galactorrhea, irregular periods, libido/energy changes, acromegalic features). EyeWiki

• Soon (scheduled): known sellar/parasellar lesion with any visual change; abnormal screening visual field needing confirmation. EyeWiki

---

What to eat

Eat more of (supports general optic-nerve/brain health):

1. Leafy greens (lutein/zeaxanthin).

2. Fatty fish 2–3×/week (omega-3s).

3. Colorful fruits/veg (antioxidants).

4. Lean proteins (for repair).

5. Whole grains & legumes (steady energy).

6. Nuts/seeds (vitamin E, magnesium).

7. Dairy/fortified foods (B12 & vitamin D if diet allows).

8. Hydration (helps headaches/fatigue).

9. Spices like turmeric/ginger (anti-inflammatory properties; modest effects).

10. Consistent meals (avoid hypoglycemia if on steroids).

Limit/avoid:

1. Tobacco (optic-nerve toxin).

2. Excess alcohol (nutritional optic neuropathy risk).

3. Very salty ultra-processed foods (blood-pressure spikes).

4. Sugary drinks (metabolic stress).

5. Mega-doses of fat-soluble vitamins without supervision.

6. Grapefruit if on certain meds (drug interactions).

7. Unregulated “stem-cell supplements” (false claims).

8. Raw/unsafe foods if immunosuppressed (infection risk).

9. Dehydration (worsens headaches).

10. Skipping prescribed hormone/immune meds because “diet will fix it” (it won’t).

---

FAQs

1) Is a junctional scotoma of Traquair permanent?
It can improve if you treat the cause early (e.g., timely tumor decompression, targeted therapy for inflammation/infection). Long-standing compression can leave permanent damage. American Journal of Neuroradiology

2) How is it different from bitemporal hemianopia?
Bitemporal loss points to a lesion in the body of the chiasm; Traquair’s pattern localizes to the junction with the optic nerve. EyeWiki

3) Which cause is most common?
Sellar masses, especially pituitary adenomas. EyeWiki

4) What test proves the diagnosis?
A formal visual-field test showing the pattern plus MRI that shows a lesion at the junction. American Journal of Neuroradiology

5) Could glaucoma cause this?
Glaucoma produces different, characteristic arcuate defects; junctional scotoma of Traquair specifically localizes to the optic nerve–chiasm junction, not the typical glaucoma anatomy. EyeWiki

6) Do glasses fix it?
No. Glasses correct blur, not neurologic field loss.

7) Can prisms help?
Prisms can help some hemianopic patterns; for this monocular temporal hemifield, training and scanning are usually more useful.

8) Will steroids always help?
Only if the cause is inflammatory/demyelinating. Steroids won’t shrink a meningioma or aneurysm and can be harmful in some infections without proper control. EyeWiki

9) What about “Wilbrand’s knee”?
Older explanations invoked a specific fiber loop; modern work emphasizes fiber involvement at the junction without relying on that concept. The take-home: the pattern still localizes to the nerve–chiasm junction. Canadian Journal of Ophthalmology

10) How fast do I need surgery?
If vision is threatened by a mass, earlier is better—your team will triage urgency. American Journal of Neuroradiology

11) Can this affect both eyes later?
Yes, if the lesion grows and involves more of the chiasm. EyeWiki

12) What recovery should I expect?
Many patients improve after decompression or disease-specific treatment, especially when pre-op duration is short and the nerve isn’t atrophic. American Journal of Neuroradiology

13) Is radiation safe near the chiasm?
Modern techniques can be safe and effective when dosed carefully by experienced teams. EyeWiki

14) Do I need lifelong follow-up?
Usually yes, for fields/OCT/MRI—to catch recurrence or progression early. EyeWiki

15) Can diet or supplements cure it?
No. They support overall nerve health but don’t remove a mass or stop aggressive inflammation by themselves.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 09, 2025.